Authors
Latest:
Dr Wilky on the Study of Zalifrelimab, Balstilimab, and Doxorubicin in Soft Tissue SarcomaBreelyn A. Wilky, MD, discusses the rationale for investigating the combination of zalifrelimab, balstilimab, and doxorubicin in patients with advanced/metastatic soft tissue sarcoma, and early results from a phase 2 trial.
Latest:
Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic SarcomaBreelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.
Latest:
Canine Caring: A Therapy Dog for Cancer PatientsPrincess Danger was never intended to be a therapy dog. She came into our home as a pet, a goofball who immediately stole our hearts. The funny thing is that she not only stole our hearts, but that of anyone who met her.
Latest:
FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLCDrs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.
Latest:
Remote Monitoring Enhances Care for Patients With Head and Neck CancerIf clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.
Latest:
Dr Van Tine on the SPEARHEAD-1 Trial of Afami-Cel in Advanced Synovial SarcomaBrian A. Van Tine, MD, PhD, discusses findings from the overall survival analysis of the phase 2 SPEARHEAD-1 trial in patients with advanced synovial sarcoma.
Latest:
Dr. Brian Baumann on the Impact of Skin Cream Use Prior to RadiationBrian Baumann, MD, medical oncologist, University of Pennsylvania, discusses the impact of skin creams on radiation.
Latest:
Dr. Crompton on the Potential for Liquid Biopsies in Pediatric SarcomasBrian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the potential of liquid biopsies in the treatment of pediatric patients with sarcoma.
Latest:
Dr. Chapin on Impact of Active Surveillance in Field of Prostate CancerBrian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.
Latest:
Dr. Durie on a More Sensitive Automated Flow Cytometry MRD TestBrian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.
Latest:
ASH Interview SeriesThe December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.
Latest:
Dr. Hemphill on Molecular Profiling for Gastric Cancer TreatmentBrian Hemphill, MD, clinical oncologist, Tennessee Oncology, discusses molecular profiling for gastric cancer treatment.
Latest:
Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCCBrian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.
Latest:
Renal Cell Carcinoma: Future Evolutions in CareShared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.
Latest:
Focal Therapy Evolves Into More Precise Treatment in Prostate CancerHistorically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.
Latest:
Is Your Practice Ready for New Rules on Hazardous Drug ManagementAmong community oncology practices, the US Pharmacopeia Convention’s General Chapter draft guidelines have already raised the bar for hazardous drug management and imposed costs for compliance.
Latest:
Dr. Leyland-Jones on Breast Cancer Risk Assessment ToolsBrian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.
Latest:
Dr. Shuch on the Impact of the SURTIME Trial in Advanced RCCBrian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses the impact of the phase III SURTIME study in advanced renal cell carcinoma (RCC).
Latest:
Dr. Slomovitz on the Role of Surgery in Endometrial CancerBrian M. Slomovitz, MD, discusses the role of surgery in women with endometrial cancer.
Latest:
ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial DesignBrian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.
Latest:
Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI CancersBrian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.
Latest:
Dr. Nussenbaum on Organ Preservation for Patients With Larynx CancerBrian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.
Latest:
Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case ReportThis is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Latest:
Dr. Orr on Ongoing Biomarker Research in Ovarian CancerBrian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.
Latest:
Dr Rini on the FDA Approval of Belzutifan in Relapsed/Refractory RCCBrian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.
